Page last updated: 2024-08-24

tenofovir and Disbacteriosis

tenofovir has been researched along with Disbacteriosis in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baeten, JM; Balkus, JE; Bukusi, E; Celum, C; Cohen, CR; Donnell, D; Fiedler, T; Fredricks, DN; Heffron, R; Kiarie, J; Lingappa, J; McClelland, RS; Mugo, N; Munch, M	1
Heffron, R; Velloza, J	1
Brenchley, JM; Calantone, N; Carmack, K; DiNapoli, SR; Estes, JD; Gallagher, J; Klase, ZA; Klatt, NR; McCune, JM; Ortiz, AM; Paiardini, M; Perkins, MR; Riddick, NE; Vinton, CL; Vujkovic-Cvijin, I	1

Reviews

1 review(s) available for tenofovir and Disbacteriosis

Article	Year
The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women. Current HIV/AIDS reports, 2017, Volume: 14, Issue:5 Topics: Anti-HIV Agents; Dysbiosis; Female; HIV Infections; Humans; Microbiota; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; Tenofovir; Vagina	2017

Trials

1 trial(s) available for tenofovir and Disbacteriosis

Article	Year
Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study. The lancet. HIV, 2017, Volume: 4, Issue:10 Topics: Adult; Anti-HIV Agents; Dysbiosis; Emtricitabine; Female; Gardnerella vaginalis; HIV Infections; HIV Seropositivity; HIV-1; Humans; Kenya; Microbiota; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Partners; Tenofovir; Uganda; Vagina; Vaginosis, Bacterial	2017

Article

Year

Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: a post-hoc analysis of the randomised, placebo-controlled Partners PrEP Study.

The lancet. HIV, 2017, Volume: 4, Issue:10

Topics: Adult; Anti-HIV Agents; Dysbiosis; Emtricitabine; Female; Gardnerella vaginalis; HIV Infections; HIV Seropositivity; HIV-1; Humans; Kenya; Microbiota; Pre-Exposure Prophylaxis; Prospective Studies; Sexual Partners; Tenofovir; Uganda; Vagina; Vaginosis, Bacterial

2017

Other Studies

1 other study(ies) available for tenofovir and Disbacteriosis

Article	Year
IL-21 and probiotic therapy improve Th17 frequencies, microbial translocation, and microbiome in ARV-treated, SIV-infected macaques. Mucosal immunology, 2016, Volume: 9, Issue:2 Topics: Animals; Anti-Retroviral Agents; Bacterial Translocation; Cell Proliferation; Combined Modality Therapy; Dysbiosis; Emtricitabine; Gastrointestinal Microbiome; Gastrointestinal Tract; Immunity, Mucosal; Interleukins; Macaca nemestrina; Probiotics; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Th17 Cells	2016

Article

Year

IL-21 and probiotic therapy improve Th17 frequencies, microbial translocation, and microbiome in ARV-treated, SIV-infected macaques.

Mucosal immunology, 2016, Volume: 9, Issue:2

Topics: Animals; Anti-Retroviral Agents; Bacterial Translocation; Cell Proliferation; Combined Modality Therapy; Dysbiosis; Emtricitabine; Gastrointestinal Microbiome; Gastrointestinal Tract; Immunity, Mucosal; Interleukins; Macaca nemestrina; Probiotics; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Th17 Cells

2016